Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

Bernard Zinman; Athena Philis-Tsimikas; Bertrand Cariou; Yehuda Handelsman; Helena W Rodbard; Thue Johansen; Lars Endahl; Chantal Mathieu; NN1250-3579 (BEGIN Once Long) Trial Investigators; Ulrik Pedersen-Bjergaard

doi:10.2337/dc12-1205

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu, NN1250-3579 (BEGIN Once Long) Trial Investigators, Ulrik Pedersen-Bjergaard

335 Citationer (Scopus)

Abstract

To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs).

Originalsprog	Engelsk
Tidsskrift	Diabetes Care
Vol/bind	35
Udgave nummer	12
Sider (fra-til)	2464-71
Antal sider	8
ISSN	0149-5992
DOI	https://doi.org/10.2337/dc12-1205
Status	Udgivet - 2012

Adgang til dokumentet

10.2337/dc12-1205

Citationsformater

Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., NN1250-3579 (BEGIN Once Long) Trial Investigators, & Pedersen-Bjergaard, U. (2012). Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care, 35(12), 2464-71. https://doi.org/10.2337/dc12-1205

Zinman, B, Philis-Tsimikas, A, Cariou, B, Handelsman, Y, Rodbard, HW, Johansen, T, Endahl, L, Mathieu, C, NN1250-3579 (BEGIN Once Long) Trial Investigators & Pedersen-Bjergaard, U 2012, 'Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)', Diabetes Care, bind 35, nr. 12, s. 2464-71. https://doi.org/10.2337/dc12-1205

@article{5b5bfca0bbfb4f4cb1186e8dbc4cfaab,

title = "Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)",

abstract = "To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs).",

author = "Bernard Zinman and Athena Philis-Tsimikas and Bertrand Cariou and Yehuda Handelsman and Rodbard, {Helena W} and Thue Johansen and Lars Endahl and Chantal Mathieu and {NN1250-3579 (BEGIN Once Long) Trial Investigators} and Ulrik Pedersen-Bjergaard",

year = "2012",

doi = "10.2337/dc12-1205",

language = "English",

volume = "35",

pages = "2464--71",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "12",

}

TY - JOUR

T1 - Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes

T2 - a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

AU - Zinman, Bernard

AU - Philis-Tsimikas, Athena

AU - Cariou, Bertrand

AU - Handelsman, Yehuda

AU - Rodbard, Helena W

AU - Johansen, Thue

AU - Endahl, Lars

AU - Mathieu, Chantal

AU - NN1250-3579 (BEGIN Once Long) Trial Investigators

AU - Pedersen-Bjergaard, Ulrik

PY - 2012

Y1 - 2012

N2 - To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs).

AB - To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs).

U2 - 10.2337/dc12-1205

DO - 10.2337/dc12-1205

M3 - Journal article

C2 - 23043166

SN - 0149-5992

VL - 35

SP - 2464

EP - 2471

JO - Diabetes Care

JF - Diabetes Care

IS - 12

ER -

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater